PF-Atlas › Treatments › Rapamycin/mTOR Inhibition
Rapamycin/mTOR Inhibition
mTOR inhibition reduces cellular senescence, autophagy dysfunction, and fibroblast proliferation in lung
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I/II
Evidence level
Level 2 (Repositioning)
Mechanism class
mTOR inhibition reduces cellular senescence, autophagy dysfunction, and fibroblast proliferation in lung
Timeline
2-3 years
Risk profile
Low-Medium
Developer
Multiple
Key researchers
Multiple
Overview
FDA-approved immunosuppressant. Reduces lung fibrosis in multiple animal models. Inhibits mTORC1 driving fibroblast proliferation and collagen synthesis. Extends lifespan in every model organism tested. Inhaled formulation under development to reduce systemic immunosuppression.
How Rapamycin/mTOR Inhibition fits into IPF treatment
Rapamycin/mTOR Inhibition is classified as Level 2 (Repositioning) at the Phase I/II stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Rapamycin/mTOR Inhibition for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.